EcoDrugPlus

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSPEMG00000027052
Gene Symbol: HTR1B
3 Cross references
245 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSPEMG00000007260
Gene Symbol: HTR1F
3 Cross references
145 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSPEMG00000011245
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSPEMG00000018290
Gene Symbol: HTR4
3 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSPEMG00000030608
Gene Symbol: HTR5A
3 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSPEMG00000011829
Gene Symbol: HTR7
3 Cross references
219 Possible Orthologues:

60s Ribosomal Protein L30

Ensembl ID : ENSPEMG00000022132
Gene Symbol: LOC102919450
2 Cross references
203 Possible Orthologues:

60s Ribosomal Protein L30

Ensembl ID : ENSPEMG00000014084
Gene Symbol: LOC102919450
2 Cross references
206 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSPEMG00000028406
Gene Symbol: LOC102910638
2 Cross references
179 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSPEMG00000027273
Gene Symbol: LOC102910638
2 Cross references
16 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPEMG00000023476
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSPEMG00000024677
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).